CUTISS Revenue
Biotechnology Research • 
Schlieren, Zurich, Switzerland • 51-100 Employees
CUTISS revenue & valuation
| Annual revenue | $6,200,000 |
| Revenue per employee | $107,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $19,900,000 |
| Total funding | $66,400,000 |
Key Contacts at CUTISS
Daniela Marino
Chief Executive Officer
Fabienne Hartmann-Fritsch
Co-Founder
Joaquin Urdinez
Director Of Operations
Timo Rey
Project Manager Automation - Associate Director
Kurt Jacobs
Gmp Manager - Head Of Production
Ilja Hohenfeld
Director Of Clinical Development
Company overview
| Headquarters | Grabenstrasse 11, Schlieren, ZH 8952, CH |
| Phone number | +41442443660 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2017 |
| Employees | 51-100 |
| Socials |
CUTISS Email Formats
CUTISS uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@cutiss.swiss), used 52.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@cutiss.swiss | 52.4% |
{first name}.{last name} | john.doe@cutiss.swiss | 47.6% |
About CUTISS
CUTISS is a late-stage clinical TechBio company and the only one transforming skin surgery and advanced dermatology with revolutionary skin tissue therapeutics. We are developing the first BIO personalized and automated skin tissue therapy for patients requiring skin surgery for a large spectrum of indications- from severe burns to reconstructive and aesthetic procedures. Our lead product denovoSkin™ is a first-in-class, bioengineered, personalized skin tissue therapy designed to improve patient outcomes and redefine the standard of care in skin surgery. Currently in Phase 3 clinical trials in the European Union, it has Orphan Drug Designation for the treatment of burns from Swissmedic, the EMA, and the US FDA. CUTISS is also pioneering the TECH automation of skin tissue bioengineering, developing the world’s first machine capable of fully automating the manufacturing process. This breakthrough ensures scalability, accessibility and cost-efficiency, and supports attractive unit economics. Our proprietary TECHBIO platform offers growth opportunities in other areas of regenerative medicine, from space research to non-healthcare applications (tissues for industry). Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) and University Children’s Hospital. Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over $90 million from private investors, family offices and public bodies.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
CUTISS has 30 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore CUTISS's funding history, including investment rounds, total capital raised, and key backers.
CUTISS Tech Stack
Discover the technologies and tools that power CUTISS's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress themes
JavaScript libraries
Hosting
Authentication
Video players
JavaScript libraries
JavaScript libraries
Maps
Page builders
JavaScript libraries
Norway
Netherlands
Germany
United States
United Kingdom
Frequently asked questions
4.8
40,000 users
